Editorial: Embracing Scrutiny by Goehl, Thomas J.
Scientists are accustomed to scrutiny such as experimental protocol
reviews, oversight on research conduct, and critiques provided during
the peer-review publication process. We especially anticipate the post-
publication period during which others attempt to reproduce, vali-
date, and then build on our work. All this scrutiny is basic to
establishing the credibility of our findings. 
We therefore should not be put off by the greater attention now
being focused on full disclosure of competing financial interests.
What is essential to us as scientists is credibility. If our work is to
contribute to the scientific and medical knowledge base, full disclo-
sure is just one more process that must be embraced to establish and
maintain the credibility of scientific and medical research.
“The potential for conflict of interest can exist whether or not an
individual believes that the relationship affects his or her scientific
judgment” (Davidoff et al. 2001); this quote should be the rule upon
which authors lean when deciding on the necessity of providing a
financial interest disclosure. Authors should also realize that disclosing
financial support does not automatically diminish the credibility of
the research. However, failure to disclose a competing financial inter-
est that is subsequently discovered immediately opens the authors to
questions about objectivity. 
The need for full disclosure has become even more compelling as
commercial organizations provide an increasing percentage of research
support. Recognizing the growing importance of full disclosure, EHP
clarified its policies in 2003. We feel that our disclosure requirements,
which focus only on competing financial interests, are clear. However,
a recent survey of the disclosure statements of some of our authors
raised doubts about compliance. 
The Center for Science in the Public Interest (CSPI 2004) sur-
veyed four top medical and scientific journals: the New England
Journal of Medicine, the Journal of the American Medical Association
(JAMA), EHP, and Toxicology and Applied Pharmacology. The
author of the report, Merrill Goozner, was quoted in USA Today
(Davis 2004) as saying that “these journals were picked because they
have the best policies.” 
The CSPI investigative study covered December 2003 through
February 2004, during which time EHP published 37 scientific stud-
ies. In a letter to EHP, Goozner (2004) stated that 
Only 2 of the studies indicated they were funded by industry, and 2 studies
included conflict of interest disclosure statements for at least some of the
authors. … The CSPI investigated the first and last authors involved in the
35 studies who did not disclose conflicts of interest. Our investigation revealed
at least 3 articles (8.6%) where either the first or last authors should have dis-
closed conflicts in accordance with the disclosure policy.
A fourth article was noted, but not included, because the issue
identified would require a very strict interpretation of conflict of
interest policies.
In an e-mail to Goozner, I expressed EHP’s gratitude for the work
done by the CSPI to help EHP achieve its goal of full disclosure of
competing financial interests. I mentioned that we have a standing
policy that encourages our readership to scrutinize disclosure issues. I
further noted the difficulty that journal editorial offices would have if
we undertook the task of checking on the financial interests of each of
our authors. I promised Goozner that we would discuss this issue with
our editorial board members and publish his letter along with
responses that we would solicit from the named authors. These letters
appear in this issue of EHP beginning on page A794.
The authors named by the CSPI (2004) have provided explana-
tions for why they did not provide disclosure to EHP. After careful
review of all the responses and discussions with our editorial board
members, I am confident that there were no
willful attempts to hide any competing finan-
cial interests. I judge that the authors named
in the CSPI report (CSPI 2004) have made
good faith efforts to comply with EHP disclo-
sure policy. 
However, lessons learned from examination of the four cases
identified in the CSPI report (CSPI 2004) do provide guidance for
future authors. In reporting affiliations, authors must ensure that
they see the final formatted manuscript before submission. In decid-
ing how in-depth their funding sources should be investigated,
authors are expected to make a diligent effort to identify sources of
funding and report that information. However, when funds come
from a funding group that combines contributions from multiple
sources, a failure to note a minor contributor is understandable. The
probability is low that this minor percentage could impact the
research findings or the personal finances of an author. Another clear
requirement is that any relationship that could be perceived to have
the potential for improperly influencing an author’s research should
always be reported. In regard to patent disclosures, only existing, rel-
evant patents issued before submission of a paper need to be dis-
closed. The issue of disclosure is quite complex. I counsel authors to
always err on the side of caution. When in doubt, report!
Considering the issues raised by the CSPI report (CSPI 2004), we
feel that it is appropriate for EHP to continue to update our disclosure
policy. We now clearly instruct our authors to err on the sign of cau-
tion, and we have added the admonition that authors are to disclose all
competing financial interests that might in any way be perceived as rep-
resenting a competing financial interest. As has been our practice, EHP
will continue to publish all disclosures made by our authors. 
Our previous policy did not outline specific punitive measures that
would be taken when our policies are violated. Because we feel that full
disclosure is an absolute requirement, we are now adding clear conse-
quences for any ethical violations. From now on, we will impose a 3-year
ban on publication on authors who willfully fail to disclose a competing
financial interest. Implementation of the ban will be made in consulta-
tion with our editorial board. If complete disclosure of possible conflicts
would have caused the journal to have rejected the manuscript, the paper
will be retracted. If the paper is not retracted but an ethical omission has
occurred, an Expression of Concern will be written, published in the
journal, and added to the online version of the article.
Once again, I encourage the scientific community to embrace scrutiny
of our competing financial interests as we embrace the scrutiny of our
research. Full disclosure is in the best interest of the individual scientists,
the journals, and society, which must have complete faith that our research
is not only of the highest quality but also is open, honest, and unbiased. 
Thomas J. Goehl
Editor-in-Chief, EHP
Research Triangle Park, North Carolina
E-mail: goehl@niehs.nih.gov 
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